Table 1.
Patient characteristics
| All patients | With LGE | No LGE | |
|---|---|---|---|
| 141 | 36 | 105 | |
| Male, n (%) | 108 (76.6) | 30 (83.3) | 78 (25.7) |
| Female, n (%) | 33 (23.4) | 6 (16.7) | 27 (25.7) |
| Age (years) | 56.1 ± 13.3 | 59.7 ± 11.2 | 54.8 ± 13.8 |
| Cardiovascular risk factors, n (%) | |||
| Diabetes mellitus | 23 (16.3) | 9 (25.0) | 14 (13.3) |
| Arterial hypertension | 55 (39.0) | 13 (36.1) | 42 (40.0) |
| Hypercholesterolemia | 53 (37.6) | 14 (38.9) | 39 (37.1) |
| Smoking | 41 (27.5) | 12 (30) | 29 (26.6) |
| Familial disposition | 21 (14.9) | 8 (22.2) | 13 (12.4) |
| BMI (kg/m2) | 26.7 ± 4.9 | 26.4 ± 4.3 | 26.8 ± 5.1 |
| NYHA class I, n (%) | 17 (12.1) | 5 (13.9) | 12 (11.4) |
| NYHA class II, n (%) | 16 (11.3) | 4 (11.1) | 12 (11.4) |
| NYHA class III, n (%) | 65 (46.1) | 17 (47.2) | 48 (45.7) |
| NYHA class IV, n (%) | 43 (30.5) | 10 (27.8) | 33 (31.4) |
| QRS >110 ms | 94 (66.7) | 29 (80.6) | 65 (61.9) |
| QTc >440 ms | 65 (46.1) | 18 (50.0) | 47 (44.8) |
| ACE-inhibitor, n (%) | 123 (87.2) | 33 (91.7) | 90 (85.7) |
| Beta-blocker, n (%) | 127 (90.1) | 33 (91.7) | 94 (89.5) |
| Spironolactone, n (%) | 105 (74.5) | 28 (77.8) | 77 (73.3) |
| Diuretic, n (%) | 127 (90.1) | 32 (88.9) | 95 (90.5) |
| Phenprocoumone, n (%) | 69 (48.9) | 23 (63.9) | 46 (43.8) |
BMI, body mass index; NYHA, New York Heart Association; ACE, angiotensin-converting enzyme.